Article Per Year (5 Year)
p-Index From 2021 - 2026
0.444
P-Index
This Author published in this journals
All Journal Biomedical Journal of Indonesia Bioscientia Medicina : Journal of Biomedicine and Translational Research Bioscientia Medicina : Journal of Biomedicine and Translational Research Bali Dermatology Venereology and Aesthetic Journal
Inda Astri Aryani
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Neuroscience Public Health

Published : 4 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 4 Documents
Search

 1 
Efficacy of SEBCLAIRA® Cream for Moderate Seborrhoeic Dermatitis on The Face as An Adjuvant Therapy (Randomised Clinical Trial, Double Blind) Inda Astri Aryani; Yulia Farida Yahya; Nina Roiana; Radema A Pranata
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 2 No. 2 (2018): Bioscientia Medicina: Journal of Biomedicine and Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32539/bsm.v2i2.47

Abstract

Background: Seborrhoeic dermatitis (SD) is a chronic papulosquamous inflammatory disease which resistant to medical treatment. Various treatment such as topical corticosteroid, antifungal and calcineurin inhibitor has been widely practiced and gives varying results Objective: Our objective was to compare the efficacy of Sebclaira® and topical hydrocortisone 2,5% for management of moderate SD on the face Methods: A randomised clinical trial, controlled, double blind study was performed for four weeks. We assessed the efficacy and side effects of these topical treatment. The severity of SD was evaluated using Seborrhea Area Severity Index-Facial (SASI-F) score. The severity of pruritus was evaluated using Visual Analogue Scale. Demographic characteristics, baseline SASI-F and VAS were recorded in the medical record. Results: A 34 patients (14 males, 20 females) with moderate SD on the face completed the four weeks study. The mean of SASI T2 and VAS score of the Sebclaira® group was significantly lower than Hydrocortisone 2.5% group with p = 0.000 and p = 0.000 respectively. Tolerance between Sebclaira® and Hydrocortisone 2.5% showed insignificant results (p = 1.000) Conclusions: The longer application of Sebclaira® was significantly more effective to improve moderate SD
Efficacy of SEBCLAIRA® Cream for Moderate Seborrhoeic Dermatitis on The Face as An Adjuvant Therapy (Randomised Clinical Trial, Double Blind) Inda Astri Aryani; Yulia Farida Yahya; Nina Roiana; Radema A Pranata
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 2 No. 2 (2018): Bioscientia Medicina: Journal of Biomedicine and Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32539/bsm.v2i2.47

Abstract

Background: Seborrhoeic dermatitis (SD) is a chronic papulosquamous inflammatory disease which resistant to medical treatment. Various treatment such as topical corticosteroid, antifungal and calcineurin inhibitor has been widely practiced and gives varying results Objective: Our objective was to compare the efficacy of Sebclaira® and topical hydrocortisone 2,5% for management of moderate SD on the face Methods: A randomised clinical trial, controlled, double blind study was performed for four weeks. We assessed the efficacy and side effects of these topical treatment. The severity of SD was evaluated using Seborrhea Area Severity Index-Facial (SASI-F) score. The severity of pruritus was evaluated using Visual Analogue Scale. Demographic characteristics, baseline SASI-F and VAS were recorded in the medical record. Results: A 34 patients (14 males, 20 females) with moderate SD on the face completed the four weeks study. The mean of SASI T2 and VAS score of the Sebclaira® group was significantly lower than Hydrocortisone 2.5% group with p = 0.000 and p = 0.000 respectively. Tolerance between Sebclaira® and Hydrocortisone 2.5% showed insignificant results (p = 1.000) Conclusions: The longer application of Sebclaira® was significantly more effective to improve moderate SD
Management of diabetic foot ulcers: dermatology perspective Adi Agung Anantawijaya Daryogo; Fitriani; Soenarto Kartowigno; Inda Astri Aryani; Yulia Farida Yahya; Sarah Diba; Aurelia Stephanie
Bali Dermatology Venereology and Aesthetic Journal BDVJ - Vol. 4 No. 2 (December 2021)
Publisher : Explorer Front

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.51559/875dt635

Abstract

Diabetes mellitus (DM) is a chronic and complex disease that affects various parts of the body. It can lead to multiple systemic complications and also cutaneous manifestation. Diabetic foot ulcer (DFU) is one of the most devastating complications of DM in dermatology. The main etiology is an increase in plasma glucose, risk factors, or comorbidities due to DM itself. Neglected DFU can lead to further complications, including high amputation and mortality rates; thus, the healing of ulcers is the main objective of the treatment. Management is divided into the standard of care and adjuvant therapies. This study aims to optimize DFU management, so it can provide proper treatment and prevent complications.
Comparative Susceptibility of Staphylococcus aureus and S. pyogenes to Musa paradisiaca Linn Leaf Extract and Fusidic Acid in Impetigo Patients Inda Astri Aryani; Winny Astria, Maretha; Novriani, Rina; Amelinda, Aulia Rosa
Biomedical Journal of Indonesia Vol. 12 No. 1 (2026): Vol 12, No 1, 2026 (In Press)
Publisher : Fakultas Kedokteran Universitas Sriwijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32539/bji.v12i1.298

Abstract

Introduction. An estimated 12% of the world’s population is at risk of experiencing impetigo. The prevalence of impetigo in developing countries ranges from 111 to 140 million cases. Impetigo often occurs in children aged 2-5 years. One way to overcome this condition involves using natural products or phytochemicals that are effective, safe, and economical. One of the Indonesian plants that can be used as an alternative medicine with antibacterial effects is the kepok banana leaves (Musa paradisiaca Linn). This study aimed to assess the susceptibility of S. aureus and S. pyogenes to the antimicrobial potential of the extract of M. paradisiaca leaf extract and fusidic acid using isolates from impetigo patients. Methods. This in vitro experimental study used a post-test-only control-group design. Bacterial isolates were obtained from impetigo patients and tested using the disk diffusion method following CLSI standards. Group comparisons were conducted using the Kruskal–Wallis test followed by Mann–Whitney U tests. A p-value < 0.05 was considered statistically significant. Results. Bivariate analysis showed a significant difference in the susceptibility of S. aureus between fusidic acid and M. paradisiaca extract (p < 0.05), where fusidic acid demonstrated larger inhibition zones. Similarly, a significant difference was observed for S. pyogenes (p < 0.05). However, there was no significant difference between the 50% and 100% extract concentrations. Conclusion. M. paradisiaca leaf extract exhibits antibacterial activity against S. aureus and S. pyogenes, but is significantly less effective than standard fusidic acid treatment in vitro.
Co-Authors Adi Agung Anantawijaya Daryogo Amelinda, Aulia Rosa Aurelia Stephanie Fitriani Nina Roiana Novriani, Rina Radema A Pranata Sarah Diba Soenarto Kartowigno Winny Astria, Maretha Yulia Farida Yahya